Antitumoral Activity of the Novel BTK Inhibitor TG-1701 is Associated with Disruption of Ikaros Signaling and Improvement of Anti-CD20 Therapy in B-cell Non-Hodgkin Lymphoma By admin / 06/18/2021
Updated Results of the Selective Bruton Tyrosine kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies By admin / 06/18/2021
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 ULTIMATE I and II Trials By admin / 06/18/2021
Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies By admin / 06/11/2021
Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib(U2) in Patients (pts) with B-cell Malignancies By admin / 06/04/2021
VIDEO: Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies By admin / 06/04/2021
Efficacy and Safety of Ublituximab vs Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results from Two Phase 3 Studies ULTIMATE I & ULTIMATE II American Academy of Neurology By admin / 04/17/2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients with Relapsed/Refractory Indolent Lymphoma By admin / 03/09/2021
A Phase 3, Randomized Trial of Ublituximab Plus Ibrutinib for Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukaemia By admin / 02/22/2021
A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) By admin / 12/07/2020
